Pilot Trial of Infusional 5-Fluorouracil, Interleukin-2, and Subcutaneous Interferon-α for Advanced Renal Cell Carcinoma
| Autor: | Anthony Y. Smith, Laurence Elias, Betsy Morrison, Kathleen K. Altobelli, Mitchell Binder, Douglas Clark, Aroop Mangalik |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Alpha interferon Pilot Projects Gastroenterology Drug Administration Schedule Renal cell carcinoma Internal medicine Antineoplastic Combined Chemotherapy Protocols Carcinoma Humans Medicine Infusions Intravenous Carcinoma Renal Cell Interferon alfa Aged Kidney Chemotherapy business.industry Interferon-alpha Middle Aged medicine.disease Survival Analysis Kidney Neoplasms Surgery Regimen medicine.anatomical_structure Oncology Fluorouracil Interleukin-2 Female business medicine.drug |
| Zdroj: | American Journal of Clinical Oncology. 22:156-161 |
| ISSN: | 0277-3732 |
| DOI: | 10.1097/00000421-199904000-00010 |
| Popis: | The authors developed an outpatient, three-drug combination regimen for advanced renal cell carcinoma. Treatment was administered for 5 days each week for 4 weeks, followed by 2-week rests. Each weekly treatment consisted of 5-fluorouracil 1,750 mg/m2 continuous intravenous infusion for 24 hours followed by interleukin-2 6 mIU/m2 per day continuous intravenous infusion for 4 days, and interferon-alpha2b 6 mU/m2 subcutaneously on days 1, 2, and 5. This trial was undertaken to assess tolerability to this regimen and obtain a preliminary assessment of its effectiveness. Most patients required some dose adjustments (especially of cytokines), treatment interruptions, or both. Toxicities were as would be expected from individual drug profiles with only mild to moderate hematologic toxicities. Among 16 patients with renal cell carcinoma treated, four had major (clinical partial response) responses, one of which was demonstrated to be a pathologic clinical response after surgical resection of a residual mass. Estimated median survival time of all patients was 93 weeks. Response and survival were correlated with known clinical risk factors. Responding patients were noted to be significantly older in age (X = 61.75 years) than nonresponders (X = 48.92 years). There was no correlation between age and other clinical risk factors, treatment tolerance, or survival. The authors conclude that this three-drug regimen is a practical, tolerable, and promising regimen for further study in renal cell carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|